News & Updates

Ingestible vital sign monitor to aid in diagnosis of sleep-related respiratory disorders

02 Dec 2023 by

A wireless, capsule-like ingestible device can measure multiple vital signs from within the gastrointestinal tract, having the potential to diagnose sleep-related respiratory disorders and capture life-threatening events such as apnoea or opioid overdose, according to a study.

Ingestible vital sign monitor to aid in diagnosis of sleep-related respiratory disorders

02 Dec 2023

Novel microbiome technology boosts Clostridioides difficile cure rate to >90 percent

01 Dec 2023 by

A novel microbiome technology developed by researchers at the Chinese University of Hong Kong (CUHK) enhances faecal microbiota transplantation (FMT) success rate to >90 percent in patients with recurrent Clostridioides difficile infection (CDI). FMT with the novel technology will become available in public hospitals in Hong Kong.

Novel microbiome technology boosts Clostridioides difficile cure rate to >90 percent

01 Dec 2023

Hepatocellular carcinoma risk diminishes with time following HCV eradication

30 Nov 2023

Among individuals with cirrhosis and cured hepatitis C virus (HCV) infection, the risk of hepatocellular carcinoma tapers off progressively through 6 years after HCV eradication, as shown in a study. However, the risk remains above thresholds that require screening.

Hepatocellular carcinoma risk diminishes with time following HCV eradication

30 Nov 2023

Mediterranean diet helps with gastrointestinal, psychological symptoms in IBS

30 Nov 2023

Adopting a Mediterranean diet is feasible and may be beneficial to individuals with irritable bowel syndrome (IBS), with a study suggesting that the diet improves gastrointestinal and psychological symptoms in this population.

Mediterranean diet helps with gastrointestinal, psychological symptoms in IBS

30 Nov 2023

Elafibranor for primary biliary cholangitis scores high in phase III trial

29 Nov 2023 by

The oral, dual peroxisome proliferator-activated receptor-α/δ agonist elafibranor improves biomarkers of cholestasis and quells itching in patients with primary biliary cholangitis, while having an acceptable safety profile, as shown in the phase III ELATIVE study.

Elafibranor for primary biliary cholangitis scores high in phase III trial

29 Nov 2023

Endoscopic ultrasound-guided CPN effective for abdominal pain in pancreatic cancer

29 Nov 2023

Endoscopic ultrasound-guided celiac plexus neurolysis added to medical management (EUS-CPN+MM) provides beneficial effects for abdominal pain in patients with unresectable pancreatic cancer at 4 and 12 weeks, reports a recent study.

Endoscopic ultrasound-guided CPN effective for abdominal pain in pancreatic cancer

29 Nov 2023

Transcutaneous neuromodulation improves symptoms in functional dyspepsia

29 Nov 2023

Patients with functional dyspepsia (FD) may benefit from transcutaneous neuromodulation (TN) treatment, which can significantly improve symptoms and quality of life, according to a study.

Transcutaneous neuromodulation improves symptoms in functional dyspepsia

29 Nov 2023

Continuous vs intermittent feeding: Which is better for critically ill patients?

29 Nov 2023 by

Continuous feeding appears to be more effective than intermittent feeding in reducing the rate of mortality in critically ill patients in the intensive care unit (ICU), reveals a study.

Continuous vs intermittent feeding: Which is better for critically ill patients?

29 Nov 2023

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

28 Nov 2023 by

Long-term monthly treatment with givosiran has good tolerability and offers continuous improvements to patients with acute hepatic porphyria (AHP), results of the phase III ENVISION trial have shown.

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

28 Nov 2023

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance

27 Nov 2023

For patients with ulcerative colitis who are receiving vedolizumab, dose optimization may not be required in the presence of early nonresponse to treatment as well as high drug clearance, according to data from the phase IV ENTERPRET study.

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance

27 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Ingestible vital sign monitor to aid in diagnosis of sleep-related respiratory disorders

Ingestible vital sign monitor to aid in diagnosis of sleep-related respiratory disorders

Novel microbiome technology boosts Clostridioides difficile cure rate to >90 percent

Novel microbiome technology boosts Clostridioides difficile cure rate to >90 percent

Hepatocellular carcinoma risk diminishes with time following HCV eradication

Hepatocellular carcinoma risk diminishes with time following HCV eradication

Mediterranean diet helps with gastrointestinal, psychological symptoms in IBS

Mediterranean diet helps with gastrointestinal, psychological symptoms in IBS

Elafibranor for primary biliary cholangitis scores high in phase III trial

Elafibranor for primary biliary cholangitis scores high in phase III trial

Endoscopic ultrasound-guided CPN effective for abdominal pain in pancreatic cancer

Endoscopic ultrasound-guided CPN effective for abdominal pain in pancreatic cancer

Transcutaneous neuromodulation improves symptoms in functional dyspepsia

Transcutaneous neuromodulation improves symptoms in functional dyspepsia

Continuous vs intermittent feeding: Which is better for critically ill patients?

Continuous vs intermittent feeding: Which is better for critically ill patients?

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance